SCHEMBL2522892

SCHEMBL2522892

CC(C)(C)OC(=O)NCC(=O)N1CC(NC(=O)c2ccccc2)CC1C(N)=O

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.50
SIGMAR1 Q99720 1/20 0.41
DPP4 P27487 2/20 0.40
TLR2 O60603 3/20 0.40
TLR1 Q15399 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ANPEP P15144 3/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
USP30 Q70CQ3 1/20 0.39
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRM1 P11229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14509062 1.00 MMP2 (0.50) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL2399929 1.00 MMP2 (0.50) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL2400095 0.92 MMP2 (0.52) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL2521825 0.92 MMP2 (0.52) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL14117871 0.92 MMP2 (0.52) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL3102862 0.92 MMP2 (0.52) MMP2SIGMAR1DPP4TLR2TLR1
Hydrochloric Acid SCHEMBL3108556 0.91 MMP2 (0.51) MMP2SIGMAR1DPP4TLR2TLR1
SCHEMBL2399785 0.90 MMP2 (0.64) MMP2SIGMAR1TLR2TLR1ANPEP
SCHEMBL13623377 0.90 MMP2 (0.64) MMP2SIGMAR1TLR2TLR1ANPEP
SCHEMBL10084498 0.90 MMP2 (0.64) MMP2SIGMAR1TLR2TLR1ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386539-B1 4-Aminoproline derivatives useful as lysine mimetics ZEALAND PHARMA AS (DK) 2016-07-20 EP claimed
EP-1966130-B1 MODIFIED LYSINE-MIMETIC COMPOUNDS ZEALAND PHARMA AS (DK) 2013-12-11 EP claimed
US-20130225644-A1 MODIFIED LYSINE-MIMETIC COMPOUNDS ZEALAND PHARMA A/S (DK) 2013-08-29 US claimed
EP-2386539-A2 Modified lysine-mimetic compounds Zealand Pharma A/S (DK) 2011-11-16 EP claimed
US-D647202-S1 Bone marrow harvesting device WARSAW ORTHOPEDIC, INC. (US) 2011-10-18 US claimed
EP-1966130-A2 MODIFIED LYSINE-MIMETIC COMPOUNDS Zealand Pharma A/S (DK) 2008-09-10 EP claimed
WO-2007078990-A2 MODIFIED LYSINE-MIMETIC COMPOUNDS ZEALAND PHARMA A/S (DK) 2007-07-12 WO claimed
US-20070149460-A1 Modified lysine-mimetic compounds ZEALAND PHARMA A/S (DK) 2007-06-28 US claimed
EP-2386539-A2 Modified lysine-mimetic compounds Zealand Pharma A/S (DK) 2011-11-16 EP disclosed
US-D647202-S1 Bone marrow harvesting device WARSAW ORTHOPEDIC, INC. (US) 2011-10-18 US disclosed
EP-1966130-A2 MODIFIED LYSINE-MIMETIC COMPOUNDS Zealand Pharma A/S (DK) 2008-09-10 EP disclosed
WO-2007078990-A2 MODIFIED LYSINE-MIMETIC COMPOUNDS ZEALAND PHARMA A/S (DK) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225644-A1 MODIFIED LYSINE-MIMETIC COMPOUNDS MYLK2, KCNN2, KCNN1 MMP2 1902/4885SIGMAR1 3221/4885DPP4 370/4885
US-20070149460-A1 Modified lysine-mimetic compounds MYLK2, KCNN2, KCNN1 MMP2 1902/4885SIGMAR1 3221/4885DPP4 370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.